本页面由Tiger Trade Technology Pte. Ltd.提供服务

Redhill Biopharma Ltd

0.7500
-0.0311-3.98%
盘后0.75000.00000.00%17:02 EDT
成交量:2.86万
成交额:2.27万
市值:381.92万
市盈率:-0.12
高:0.8299
开:0.8299
低:0.7500
收:0.7811
52周最高:3.31
52周最低:0.7500
股本:509.23万
流通股本:332.99万
量比:1.87
换手率:0.86%
股息:- -
股息率:- -
每股收益(TTM):-6.0249
每股收益(LYR):-6.7096
净资产收益率:-1708.61%
总资产收益率:-25.32%
市净率:-0.87
市盈率(LYR):-0.11

数据加载中...

2026/01/22

[修订]招股说明书

Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
2026/01/22

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2025/12/31

招股说明书

Form F-1 - Registration statement for certain foreign private issuers
2025/06/30

SEC问询函

Form CORRESP - Correspondence
2025/06/25

招股说明书

Form F-1 - Registration statement for certain foreign private issuers
2025/04/10

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2025/03/26

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/11/14

超过5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/08/16

SEC问询函

Form CORRESP - Correspondence
2024/06/20

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/04/08

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/02/15

SEC问询函

Form CORRESP - Correspondence
2024/02/09

招股说明书

Form F-1 - Registration statement for certain foreign private issuers
2024/02/02

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/02/01

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/01/08

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2023/10/26

SEC问询函

Form CORRESP - Correspondence
2023/08/10

SEC问询函

Form CORRESP - Correspondence
2023/06/29

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2023/04/28

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]